1. What Is the Heart Failure Market?
The Heart Failure Market covers the medicines and devices used to treat the heart failure with reduced ejection fraction HFrEF and the heart failure with preserved ejection fraction HFpEF. These together affect over 60 million people globally with the 5-year mortality that rivals many cancers. The neurohormonal antagonists ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid receptor antagonists form the guideline-directed medical therapy backbone. The newer agents include the sacubitril-valsartan ARNI, the SGLT2 inhibitors, the myosin activator omecamtiv mecarbil, and the guanylate cyclase stimulator vericiguat. Heart failure drug development has achieved the quadruple therapy guideline-directed medical therapy for HFrEF comprising the RAAS inhibitor, the beta-blocker, the MRA, and the SGLT2 inhibitor. Each of the four pillars demonstrates the individual mortality reduction. The individualised titration of all four agents achieves the combined effect for the HFrEF patient who can tolerate the combination. The HF market is advancing with the mavacamten cardiac myosin inhibitor for the symptomatic obstructive hypertrophic cardiomyopathy. The EXPLORER-HCM trial demonstrated the dynamic outflow tract gradient reduction with the symptom improvement. The FDA approved the first targeted therapy for the hypertrophic obstructive cardiomyopathy pathophysiology.
2. Heart Failure Market Size & Forecast
3. Emerging Technologies
- Quadruple guideline-directed medical therapy for HFrEF combines the ACE inhibitor or sacubitril-valsartan as the RAAS inhibitor, the beta-blocker, the spironolactone or eplerenone MRA, and the dapagliflozin or empagliflozin SGLT2 inhibitor. Each pillar demonstrates individual 15 to 20 percent mortality reduction. The combination provides the additive or greater combined effect. HFrEF management now requires the simultaneous initiation rather than the sequential step-by-step addition that allowed the patient to deteriorate before the additional agent was added.
- Mavacamten CAMZYOS cardiac myosin ATPase inhibitor reduces the excessive cross-bridge formation that the hypertrophic obstructive cardiomyopathy creates through the sarcomere hypercontractility that the pathogenic MYH7 and MYBPC3 mutations drive. The drug provides the 44 percent reduction in the left ventricular outflow tract peak gradient at rest and provocation that produces the symptom improvement. The first disease-targeted therapy addresses the hypertrophic cardiomyopathy pathophysiology rather than the symptom management that the beta-blocker and the disopyramide provide.
- SGLT2 inhibitor HFpEF treatment EMPEROR-Preserved and DELIVER trials demonstrated the composite worsening heart failure or cardiovascular death reduction that the empagliflozin and dapagliflozin achieve. The HFpEF patients had the EF above 40 and 50 percent respectively. The SGLT2 inhibitor is now the first drug class with evidence of benefit across the full ejection fraction spectrum. The benefit extends from HFrEF through HFmrEF to HFpEF.
- ATTR cardiomyopathy treatment with tafamidis Vyndaqel and Vyndamax for the transthyretin amyloid cardiomyopathy is established by the ATTR-ACT trial demonstrating 30 percent mortality reduction over 30 months. The TTR stabiliser is the first approved ATTR cardiomyopathy treatment. The treatment addresses the protein misfolding at the source.
Similar technologies are also transforming adjacent markets. Learn more in our Atrial Fibrillation Market.
4. Key Market Opportunity
Meaningful upside in the Heart Failure market is HFpEF treatment expansion, where SGLT2 inhibitors providing the first effective HFpEF therapy create a large addressable patient population previously without evidence-based pharmacotherapy. Companies with SGLT2 inhibitor HFpEF approvals capture this large underserved market. Additional momentum is centered on cardiac myosin modulator development for HCM and HFpEF. As HFpEF SGLT2 adoption expands and myosin modulator development advances, the addressable opportunity is growing from HFrEF-focused therapy toward a comprehensive heart failure pharmacotherapy across EF spectrum.
5. Top Companies in the Heart Failure Market
The following organisations hold leading positions in the Heart Failure Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Novartis
- Bayer
- AstraZeneca
- Boehringer Ingelheim
- Eli Lilly
- Pfizer
- Bristol-Myers Squibb
- Cytokinetics
- Merck
- Sanofi
- Otsuka Pharmaceutical
- Amgen
- BridgeBio Pharma
- BioMarin Pharmaceutical
- Tenax Therapeutics
6. Market Segmentation
The Heart Failure Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By EF Status | HFrEFHFpEFHFmrEF |
| By Drug Class | SGLT2 InhibitorARNIBeta-BlockerMRACardiac Myosin Activator |
| By Setting | OutpatientHospital Inpatient |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Heart Failure Market trajectory over the forecast period:
HFrEF Quadruple GDMT Simultaneous Initiation of RAAS Inhibitor, Beta-Blocker, MRA, and SGLT2 Inhibitor Each Providing 15 to 20 Percent Individual Mortality Reduction Has Shifted the Heart Failure Protocol From Sequential Step Addition to Comprehensive Programme Initiation.ACC and ESC guideline updates have endorsed the rapid uptitration of all four evidence-based HFrEF therapies simultaneously rather than sequential addition, based on data showing that the combined mortality reduction from sacubitril-valsartan, SGLT2 inhibitor, spironolactone, and carvedilol exceeds the sum of individual class benefits by addressing complementary mechanisms of ventricular remodelling, fluid retention, sympathetic activation, and mitochondrial dysfunction. Implementation trials including STRONG-HF demonstrate that rapid simultaneous initiation under close monitoring achieves safe uptitration in the majority of patients and substantially reduces 90-day rehospitalisation rates that remain unacceptably high after HF hospitalisation. The commercial implication establishes Novartis, AstraZeneca, Boehringer Ingelheim, and multiple generic manufacturers as obligate co-prescribing partners across the HFrEF quadruple therapy standard.
Mavacamten CAMZYOS Cardiac Myosin ATPase Inhibitor Reducing LVOT Gradient 44 Percent in Obstructive HCM Has Provided the First Disease-Targeted Therapy That Addresses Sarcomere Hypercontractility Pathophysiology Rather Than the Symptomatic Management That Beta-Blocker and Disopyramide Provide.AstraZeneca's dapagliflozin in DELIVER and Boehringer Ingelheim and Eli Lilly's empagliflozin in EMPEROR-Preserved both demonstrated significant reduction in cardiovascular death and heart failure hospitalisation in HFpEF patients, representing breakthrough approvals in a condition where multiple prior drug classes including aldosterone antagonists, angiotensin neprilysin inhibition, and PDE5 inhibition had failed to demonstrate benefit. The HFpEF population represents over half of all heart failure patients, and the previously empty treatment landscape created a large unmet commercial and clinical opportunity that SGLT2 inhibitor approval has partially filled. The SGLT2 HFpEF mechanism is proposed to involve ventricular stiffness reduction through osmotic diuresis and epicardial fat reduction that improves diastolic filling beyond the haemodynamic effects that prior vasodilator-class agents had tested unsuccessfully.
SGLT2 Inhibitor EMPEROR-Preserved and DELIVER Benefit Across HFpEF EF Above 40 and 50 Percent Has Made the SGLT2 Inhibitor the First Drug Class With Evidence Across the Full Ejection Fraction Spectrum From HFrEF Through HFmrEF to Preserved Ejection Fraction Heart Failure.Bristol-Myers Squibb's mavacamten demonstrated 37% absolute improvement in peak oxygen consumption in EXPLORER-HCM, establishing the first approved cardiac myosin-specific inhibitor for obstructive HCM and enabling non-surgical treatment of a condition previously requiring septal reduction procedures. Cytokinetics's aficamten demonstrated non-inferior cardiac myosin inhibition with potentially improved safety and drug-drug interaction profile in FOREST-HCM versus mavacamten's warfarin interaction concerns, and Phase 3 MAPLE-HCM data will determine whether aficamten can capture share in a market where mavacamten has established clinical proof of concept. The cardiac myosin inhibitor class may expand into non-obstructive HCM, dilated cardiomyopathy, and HFpEF if ongoing trials support efficacy beyond the obstructive HCM indication where the hypercontractility hypothesis is most mechanistically straightforward.
For related market intelligence, see the Cardiology Drug Market.
8. Segmental Analysis
By drug class, the angiotensin receptor-neprilysin inhibitor segment dominated the Heart Failure Market in 2025, as Novartis's Entresto became guideline-recommended first-line therapy for reduced ejection fraction heart failure, generating the largest branded revenue in the indication.
By EF status, the preserved ejection fraction segment is projected to register the highest growth rate through 2034, as SGLT2 inhibitors from AstraZeneca and Boehringer Ingelheim and Eli Lilly demonstrated benefit in a previously untreatable population that represents roughly half of all heart failure cases.
9. Regional Analysis
Regional demand patterns across the Heart Failure Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Heart Failure Market in 2025, accounting for approximately 44% of global revenue, attributed to US premium pricing for SGLT2 inhibitors, ARNI, and emerging cardiac myosin modulators and the large heart failure patient population. Moreover, foundational four-drug GDMT adoption is most advanced in US cardiology. In addition, HFpEF SGLT2 inhibitor adoption is leading. Regional dominance is due to this combination of pricing environment and clinical adoption.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Heart Failure Market through 2034, driven by the large heart failure patient population in China, Japan, and South Korea and expanding access to SGLT2 inhibitors and ARNI therapies through reimbursement. The region is also witnessing HFpEF SGLT2 prescribing growing. Moreover, the demographic ageing sustains heart failure prevalence growth. The combination of these demand drivers and patient scale positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Heart Failure Market was valued at USD 17.56 Bn in 2025 and is projected to reach USD 39.75 Bn by 2034, growing at a CAGR of 9.5% over the 2026–2034 forecast period.
The Heart Failure Market is projected to grow at a CAGR of 9.5% from 2026 to 2034.
North America dominated the Heart Failure Market in 2025, accounting for approximately 44% of global revenue, attributed to US premium pricing for SGLT2 inhibitors, ARNI, and emerging cardiac myosin modulators and the large heart failure patient population.
The leading companies in the Heart Failure Market include Novartis, Bayer, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Pfizer, Bristol-Myers Squibb, Cytokinetics, Merck, Sanofi, Otsuka Pharmaceutical, Amgen, BridgeBio Pharma, BioMarin Pharmaceutical, Tenax Therapeutics.
Hfref quadruple gdmt simultaneous initiation of raas inhibitor, beta-blocker, mra, and sglt2 inhibitor each providing 15 to 20 percent individual mortality reduction has shifted the heart failure protocol from sequential step addition to comprehensive programme initiation.
By drug class, the angiotensin receptor-neprilysin inhibitor segment dominated the Heart Failure Market in 2025, as Novartis's Entresto became guideline-recommended first-line therapy for reduced ejection fraction heart failure, generating the largest branded revenue in the indication.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.